OncoMatch/Clinical Trials/NCT05120596

First in Human Study of T3P-Y058-739 (T3P)

Is NCT05120596 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Pembrolizumab+T3P-Y058-739 and T3P-Y058-739 (IV) for advanced solid tumor.

Phase 1/2RecruitingT3 Pharmaceuticals AGNCT05120596Data as of May 2026

Treatment: Pembrolizumab+T3P-Y058-739 · T3P-Y058-739 (IV) · T3P-Y058-739 (IT) — This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Adequate iron stores without significant iron overload

Kidney function

Liver function

Adequate iron stores without significant iron overload; Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify